Editing Anthrax (section)

=== Monoclonal antibodies ===
In May 2009, [[Human Genome Sciences]] submitted a [[biologic license application]] (BLA, permission to market) for its new drug, [[raxibacumab]] (brand name ABthrax) intended for emergency treatment of inhaled anthrax.<ref>{{cite news |title=HGSI asks for FDA approval of anthrax drug ABthrax |agency=[[Associated Press]] |newspaper=Forbes |date=21 May 2009 |url=http://www.pharmpro.com/news/2009/05/hgsi-asks-fda-approval-anthrax-drug-abthrax |url-status=live |archive-url=https://web.archive.org/web/20141018235213/http://www.pharmpro.com/news/2009/05/hgsi-asks-fda-approval-anthrax-drug-abthrax |archive-date=18 October 2014 }}</ref> On 14 December 2012, the US Food and Drug Administration approved raxibacumab injection to treat inhalational anthrax. Raxibacumab is a [[monoclonal antibody]] that neutralizes toxins produced by ''B. anthracis''.<ref name="urlFDA approves raxibacumab to treat inhalational anthrax">{{cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm|title=FDA approves raxibacumab to treat inhalational anthrax|website=[[Food and Drug Administration]]|access-date=14 December 2012|url-status=live|archive-url=https://web.archive.org/web/20121217061133/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm|archive-date=17 December 2012}}</ref> In March 2016, FDA approved a second anthrax treatment using a monoclonal antibody which neutralizes the toxins produced by ''B. anthracis''. [[Obiltoxaximab]] is approved to treat inhalational anthrax in conjunction with appropriate [[antibacterial]] drugs, and for prevention when alternative therapies are not available or appropriate.<ref>{{cite web |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491470.htm |title=FDA approves new treatment for inhalation anthrax |author=News Release |publisher=FDA |date=21 March 2016}}</ref>